UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $513.49 million. The enterprise value is $438.04 million.
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 46.09 million shares outstanding. The number of shares has increased by 40.86% in one year.
| Current Share Class | 46.09M |
| Shares Outstanding | 46.09M |
| Shares Change (YoY) | +40.86% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 5.09% |
| Owned by Institutions (%) | 72.08% |
| Float | 36.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.51 |
| Forward PS | 4.77 |
| PB Ratio | -11.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.65
| Current Ratio | 5.65 |
| Quick Ratio | 5.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.56 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -29.80% |
| Return on Invested Capital (ROIC) | -97.24% |
| Return on Capital Employed (ROCE) | -51.97% |
| Revenue Per Employee | $390,940 |
| Profits Per Employee | -$589,068 |
| Employee Count | 235 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.28 |
Taxes
In the past 12 months, UroGen Pharma has paid $3.17 million in taxes.
| Income Tax | 3.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.56% in the last 52 weeks. The beta is 0.67, so UroGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -12.56% |
| 50-Day Moving Average | 10.65 |
| 200-Day Moving Average | 11.90 |
| Relative Strength Index (RSI) | 54.27 |
| Average Volume (20 Days) | 687,116 |
Short Selling Information
The latest short interest is 5.02 million, so 10.88% of the outstanding shares have been sold short.
| Short Interest | 5.02M |
| Short Previous Month | 5.06M |
| Short % of Shares Out | 10.88% |
| Short % of Float | 13.56% |
| Short Ratio (days to cover) | 7.74 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $91.87 million and -$138.43 million in losses. Loss per share was -$3.04.
| Revenue | 91.87M |
| Gross Profit | 82.39M |
| Operating Income | -106.86M |
| Pretax Income | -100.36M |
| Net Income | -138.43M |
| EBITDA | -106.58M |
| EBIT | -106.86M |
| Loss Per Share | -$3.04 |
Full Income StatementBalance Sheet
The company has $195.89 million in cash and $124.95 million in debt, giving a net cash position of $75.46 million or $1.64 per share.
| Cash & Cash Equivalents | 195.89M |
| Total Debt | 124.95M |
| Net Cash | 75.46M |
| Net Cash Per Share | $1.64 |
| Equity (Book Value) | -46.46M |
| Book Value Per Share | -1.01 |
| Working Capital | 195.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$107.06 million and capital expenditures -$339,000, giving a free cash flow of -$107.39 million.
| Operating Cash Flow | -107.06M |
| Capital Expenditures | -339,000 |
| Free Cash Flow | -107.39M |
| FCF Per Share | -$2.33 |
Full Cash Flow StatementMargins
Gross margin is 89.68%, with operating and profit margins of -116.31% and -150.68%.
| Gross Margin | 89.68% |
| Operating Margin | -116.31% |
| Pretax Margin | -147.23% |
| Profit Margin | -150.68% |
| EBITDA Margin | -116.01% |
| EBIT Margin | -116.31% |
| FCF Margin | n/a |